Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of curaxin CBL0137 on expression of genes in MM1.S and HeLa S3 cells

ABSTRACT: CBL0137 id non-genotoxic DNA binding compounds which directly destabilizes nucleosomes in cells. Effect of different doses of CBL0137 on the abundance of mRNA was studied in two cell types, multiple myeloma MM1.S and cervical carcinoma HeLa cell.

ORGANISM(S): Homo sapiens

PROVIDER: GSE117611 | GEO | 2018/07/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Effect of curaxin CBL0137 on expression of genes in MM1.S and HeLa S3 cells

Project description:Effect of curaxin CBL0137 on expression of genes in MM1.S and HeLa S3 cells

| PRJNA482641 | ENA

Effect of DNA binding small molecules on the genomic distribution of nucleosomes with H3K27Ac

Project description:Small molecule CBL0137 destabilizes nucleosome directly via binding to DNA. Effect of CBL0137 on nucleosomes with mark specific for more open chromatin characteristic for promoters and enhancers versus all nucleosomes H3 was measured.

2018-07-20 | GSE117409 | GEO

Effect of CBL0137 on DIPG cells

Project description:Diffuse intrinsic pontine glioma (DIPG) is an aggressive and incurable childhood brain tumor for which new treatments are needed. A high throughput drug screen of 3600 pharmaceutical compounds found that anti-malarials, including quinacrine had potent activity against DIPG neurospheres. CBL0137 is a novel anti-cancer compound developed from quinacrine, which targets Facilitates Chromatin Transcription (FACT), a chromatin remodelling complex involved in transcription, replication, and DNA repair. We have found that CBL0137 displays profound cytotoxic activity against a panel of patient derived DIPG cultures, inhibiting cell proliferation and clonogenic potential, restoring tumor suppressor TP53 and Rb activity and inducing cell death through induction of apoptosis. Moreover, in an orthotopic model of DIPG, treatment with CBL0137 significantly extended animal survival. Histone mutations leading to the loss of histone trimethylation result in epigenetic dysregulation driving DIPG tumorigenesis. Treatment with CBL0137 targets this epigenetic defect, restoring both histone H3.3 acetylation and trimethylation and leading to tumor cell death. Combined epigenetic treatment with the histone deacetylase (HDAC) inhibitor panobinostat led to inhibition of the Rb/E2F1 pathway, and increased the enzymatic activity of enhancer of zeste homolog 2 (EZH2), leading to the restoration of H3K27 trimethylation. This combination therapy had synergistic activity against DIPG neurospheres with induction of apoptosis. Consistent with the in vitro results, the combination of CBL0137 and panobinostat significantly prolonged the survival of mice bearing DIPG orthografts suggesting a potential treatment strategy for DIPG.

2021-03-07 | GSE153883 | GEO

Combination of CBL0137 and Panobinostat in DIPG

2021-02-12 | GSE153441 | GEO

Effect of CBL0137 on gene expression in mouse cells and tissues

Project description:We analyzed changes in abundance of RNAs in mouse embryonic fibroblasts (MEF) from wild type and p53 knockout mice and in lungs of NIH Swiss mice upon treatment with 1microM (cells) or 60mg/kg IV (mice) of curaxin CBL0137 for 24 hours. CBL0137 is chromatin destabilizing agent.

2017-08-18 | GSE102768 | GEO

Sulfolobus islandicus strain:MM1

Project description:Sulfolobus islandicus MM1 genome sequencing

| PRJNA346343 | ENA

Microbacterium esteraromaticum strain:MM1

Project description:Microbacterium sp. MM1 Genome sequencing

| PRJNA377799 | ENA

Effect of CBL0137 on gene expression in FACT positive and negative organs of mice

Project description:CBL0137 is chromatin destabilizing agent, which causing trapping of FACT histone chaperone in chromatin (Gasparian et all, Science TM, 2011, Safina et all, NAR, 2017). We compared effect of CBL0137 on gene expression in mouse organs, expressing FACT (testes, spleen ) or not (lung, liver) to figure out what effects of CBL0137 is due to the inhibition of FACT and which are independent of FACT.

2017-08-18 | GSE102769 | GEO

Effect of ubiquitin-activating enzyme inhibition on multiple myeloma cell line MM1.S

Project description:Resistance to proteasome inhibitors has prompted interest in blocking upstream components of the ubiquitin-proteasome pathway for the treatment of multiple myeloma (MM). We therefore evaluated the activity of TAK-243, a novel and specific inhibitor of E1 ubiquitin activating enzyme (UAE) activity, in the MM cell line MM1.S. Treatment of MM1.S with 25 nM TAK-243 for 24 hr caused extensive changes in gene expression, highly uniform between triplicates.

2019-05-01 | GSE126254 | GEO

Morganella morganii strain:Mm1

Project description:Morganella morganii strain:Mm1 Genome sequencing

| PRJNA553660 | ENA